Vaxcyte, Inc. (PCVX) Stock Analysis

Wall Street Analysts Think Vaxcyte (PCVX) Could Surge 75.6%: Read This Before Placing a Bet

Wed, October 14, 2026 at 12:55 PM UTC 4 min read

Wall Street analysts have projected that Vaxcyte (PCVX) could see a significant surge of 75.6% in its stock price, driven by positive developments in its vaccine pipeline and strong market demand. This optimistic outlook highlights the potential for substantial returns, making it an attractive option for investors looking to capitalize on advancements in the biotech sector. Investors should consider these insights before making investment decisions.

Read full article →

Vaxcyte stock falls on $1B dual offering launch

Mon, October 5, 2026 at 9:26 PM UTC 2 min read

Vaxcyte (PCVX) shares declined following the announcement of a $1 billion dual offering, which includes both common stock and convertible senior notes. This move is aimed at raising capital to support the company's ongoing development and commercialization efforts. Investors may be concerned about potential dilution of their shares and the implications of increased debt, impacting the stock's performance in the near term.

Read full article →